- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05689931
Perfil de leucocitos en sangre en el asma eosinofílica tipo 2: influencia de la focalización sistémica de IL-5
The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.
The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Skåne County
-
Lund, Skåne County, Suecia, 22185
- The Lung and Allergy Clinic, Skåne University Hospital (SUS)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.
Descripción
Inclusion Criteria:
- Clinical diagnosis of asthma (the asthma patient arms)
- Eligible for Mepolizumab treatment as per the country-specific prescribing information (the arms with Mepolizumab)
Exclusion criteria:
- Any diagnosed infection (all arms)
- Previous history of lung disease, chronic inflammatory condition, atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling (Healthy non-asthma control subjects)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: CROSS_SECTIONAL
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Asthma patients initiating Mepolizumab treatment
Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Otros nombres:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Otros nombres:
|
|
Asthma patients already on Mepolizumab treatment
Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections |
Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma. Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Otros nombres:
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Otros nombres:
|
|
Asthma patients without Mepolizumab treatment
Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections |
Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Otros nombres:
|
|
Healthy non-asthmatic control subjects
Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Blood Eosinophil Marker Expression
Periodo de tiempo: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Basophil Marker Expression
Periodo de tiempo: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood Leukocyte Composition
Periodo de tiempo: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Blood T Lymphocyte Marker Expression
Periodo de tiempo: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio). |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Change in Blood B Lymphocyte Marker Expression
Periodo de tiempo: Baseline, Day 2, and Month 4 after mepolizumab initiation
|
Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population. |
Baseline, Day 2, and Month 4 after mepolizumab initiation
|
|
Leukocyte Total Cell Counts
Periodo de tiempo: Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
Routine clinical laboratory total leukocyte counts in peripheral blood |
Baseline, Day 2, and Month 4 after mepolizumab initiation.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Forced Expiratory Volume in 1 Second (FEV1)
Periodo de tiempo: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Expiratory Volume, 1s; (FEV1). |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Forced Vital Capacity (FVC)
Periodo de tiempo: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
Spirometry: Forced Vital Capacity (FVC) |
Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
|
|
Change in Exhaled FeNo
Periodo de tiempo: Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
Fractional exhaled NO will be measured at multiple flows |
Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jonas Erjefält, Lund University Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1072615
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .